Premium
RVO related macular edema: Rules for the patients follow up; how to choose the applied treatment?
Author(s) -
LOEWENSTEIN A
Publication year - 2014
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2014.1715.x
Subject(s) - medicine , aflibercept , ranibizumab , pseudophakia , bevacizumab , intensive care medicine , glaucoma , endophthalmitis , ophthalmology , surgery , cataract surgery , chemotherapy
The treatment of RVO has dramatically evolved during the last few years. The main evidence base therapies are antiVEGF agents (Ranibizumab, Aflibercept, and level 2 evidence for bevacizumab) and steroids (Ozurdex). Each approach has advantages and limitations, while both have good efficacy results. In the decision making of the needed treatment inflammatory as well as VEGF pathways need to be taken into consideration. The treatment is to be tailored to the individual patient taking into consideration both ocular (existence of glaucoma, if it is controlled, existence of cataract, pseudophakia, ischemia), systemic (existence of cardiovascular risk factors) and social (ability to come monthly and availability of the health care system). Results of head to head trials are awaited.